Abstract
Objectives
To investigate effects of ablation margins on local tumour progression-free survival (LTPFS) according to RAS status in patients with colorectal liver metastases (CLM).
Methods
This two-institution retrospective study from 2005–2016 included 136 patients (91 male, median age 60 years) with 218 ablated CLM. LTPFS was performed using the Kaplan–Meier method and evaluated with the log-rank test. Uni/multivariate analyses were performed using Cox-regression models.
Results
Three-year LTPFS rates for CLM with minimal ablation margin ≤10 mm were significantly worse than those with >10 mm in both mutant-RAS (29% vs. 48%, p=0.038) and wild-type RAS (70% vs. 94%, p=0.039) subgroups. Three-year LTPFS rates of mutant-RAS were significantly worse than wild-type RAS in both CLM subgroups with minimal ablation margin ≤10 mm (29% vs. 70%, p<0.001) and >10 mm (48% vs. 94%, p=0.006). Predictors of worse LTPFS were ablation margins ≤10 mm (HR: 2.17, 95% CI 1.2–4.1, p=0.007), CLM size ≥2 cm (1.80, 1.1–2.8, p=0.017) and mutant-RAS (2.85, 1.7–4.6, p<0.001).
Conclusions
Minimal ablation margin and RAS status interact as independent predictors of LTPFS following CLM ablation. While minimal ablation margins >10 mm should be always the procedural goal, this becomes especially critical for mutant-RAS CLM.
Key Points
• RAS and ablation margins are predictors of local tumour progression-free survival.
• Ablation margin >10 mm, always desirable, is crucial for mutant RAS metastases.
• Interventional radiologists should be aware of RAS status to optimize LTPFS.
Similar content being viewed by others
Abbreviations
- CLM:
-
Colorectal liver metastases
- LTP:
-
Local tumour progression
- LTPFS:
-
Local tumour progression-free survival
- RAS :
-
Rat sarcoma viral oncogene
References
Shady W, Petre EN, Gonen M et al (2016) Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. Radiology 278:601–611.
de Baere T, Tselikas L, Yevich S et al (2017) The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer 75:231–242.
Solbiati L, Ahmed M, Cova L et al (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265:958–968.
Sofocleous CT, Petre EN, Gonen M et al (2011) CT-guided Radiofrequency Ablation as a Salvage Treatment of Colorectal Cancer Hepatic Metastases Developing after Hepatectomy. J Vasc Interv Radiol 22:755–761.
Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol 27:1386–1422.
Ruers T, Van Coevorden F, Punt CJA et al (2017) Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. JNCI J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx015
Gillams AR, Lees WR (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19:1206–1213.
Wang X, Sofocleous CT, Erinjeri JP et al (2013) Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 36:166–175.
Veltri A, Sacchetto P, Tosetti I et al (2008) Radiofrequency Ablation of Colorectal Liver Metastases: Small Size Favorably Predicts Technique Effectiveness and Survival. Cardiovasc Intervent Radiol 31:948–956.
Odisio BC, Yamashita S, Huang SY et al (2017) Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 104:760–768.
Amado RG, Wolf M, Peeters M et al (2008) Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 26:1626–1634.
Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med 359:1757–1765.
Pollock CB, Shirasawa S, Sasazuki T et al (2005) Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res 65:1244–1250.
Brudvik KW, Mise Y, Chung MH et al (2016) RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol 23:2635–2643.
Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol JVIR 25:1691–1705.e4.
Knijn N, Mekenkamp LJM, Klomp M et al (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104:1020–1026.
Baas JM, Krens LL, Guchelaar H-J et al (2011) Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review. The Oncologist 16:1239–1249.
Gillams A, Goldberg N, Ahmed M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013. Eur Radiol 25:3438–3454.
Pathak S, Jones R, Tang JMF et al (2011) Ablative therapies for colorectal liver metastases: a systematic review: Ablation for colorectal liver metastases. Colorectal Dis 13:e252–e265.
Hur H, Ko YT, Min BS et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197:728–736.
Aloia TA (2006) Solitary Colorectal Liver Metastasis: Resection Determines Outcome. Arch Surg 141:460.
Funding
This study has received funding by the National Institutes of Health/National Cancer Institute under award number P30CA016672
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Bruno Odisio.
Conflict of interest
The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors has significant statistical expertise.
Informed consent
Written informed consent was obtained from all subjects (patients) in this study.
Ethical approval
Institutional Review Board approval was obtained.
Study subjects or cohorts overlap
Some study subjects have been partially previously reported in one paper: Odisio BC, Yamashita S, Huang SY, et al (2017) Br J Surg 104:760–768
Methodology
• retrospective
• observational
• multicentre study
Rights and permissions
About this article
Cite this article
Calandri, M., Yamashita, S., Gazzera, C. et al. Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol 28, 2727–2734 (2018). https://doi.org/10.1007/s00330-017-5273-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-017-5273-2